The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours.

Background

The aim of this prospective observational study was to evaluate the dosimetry benefits, changes in pulmonary function, and clinical outcome of online adaptive MR-guided SBRT.

Methods

From 11/2020-07/2022, 45 consecutive patients with 59 lesions underwent multi-fraction SBRT (3-8 fractions) at our institution. Patients were eligible if they had biopsy-proven NSCLC or lung cancer/metastases diagnosed via clinical imaging. Endpoints were local control (LC) and overall survival (OS). We evaluated PTV/GTV dose coverage, organs at risk exposure, and changes in pulmonary function (PF). Acute toxicity was classified per the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0.

Results

The median PTV was 14.4 cm

Conclusions

Online adaptive MR-guided SBRT is an effective, safe and generally well tolerated treatment option for lung tumours achieving encouraging local control rates with significantly improved target volume coverage.

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The Department of Radiation Oncology of the LMU University Hospital, LMU Munich has research agreements with ViewRay Inc., Elekta, Brainlab, and C-RAD. ViewRay Inc. did not fund this study and was not involved and had no influence on the study design, the collection or analysis of data, or on the writing of the manuscript. MN reports research grants and speaker fees/travel support from Brainlab, ViewRay, AstraZeneca. FM reports a research grant from AstraZeneca and honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab. FM serves on the advisory board of AstraZeneca, Novartis. CB reports receiving grants or contracts from ViewRay, Brainlab, and Elekta; payment or honoraria from Bristol-Myers Squibb, Roche, Merck, AstraZeneca, Opasca, C-RAD, Elekta, and ViewRay; receiving support for attending meetings or travel from Bristol-Myers Squibb, Roche, Merck, AstraZeneca, Elekta, and View Ray; and having a leadership or fiduciary role with ESTRO, all outside the submitted work. SC reports research grants and speaker fees/travel support from Elekta, Viewray and Brainlab. CE reports consulting fees from Novartis outside the submitted work.